Low-Dose Lithium: Strong Route, Thin Claim
Low-dose lithium is not proven longevity medicine, but it is a tractable approved-drug translation test case because human dosing and safety precedent already exist.
Strong route, unproven destination.
Lithium does not become an anti-aging drug because someone mutters “neuroprotection” near it. That is not a mechanism. It is a mood. Lithium is interesting here for a duller and more useful reason: it can be tested faster than a brand-new molecule still being admired in cells and mice.
What the system knows
The route is approved-drug translation: move existing compounds into human proof-of-concept through repurposing, 505(b)(2), pragmatic trials, and real-world evidence instead of waiting for de novo discovery to wake up.
Lithium fits because it already has human dosing and safety precedent. That does not mean “safe at any dose.” It does not mean “extends life.” It means low-dose mechanistic trials are more tractable than starting from nothing.
Where it is strong
The edge is high-confidence: approved-drug translation supports low-dose lithium programs. The biology is not vague hand-waving either: GSK3B-dependent signaling, neuroinflammation, microglial activation, tau phosphorylation, and possibly hippocampal ATP2A2/SERCA2 activity.
Where it is thin
There is no stored anchor quote. The material gives rationale and mechanism scope, not trial outcomes proving neuroprotection or longevity benefit. This is a pathway argument, not a victory lap.
Next step
Run human proof-of-concept trials with low-dose exposure, hard toxicity boundaries, mechanistic endpoints, and tests tied to the proposed signaling biology. Otherwise this becomes another pharmacology belief system wearing a lab coat.
Selected because the edge has high confidence for the route relationship while the actual low-dose lithium aging claim remains unproven, making it a clean example of separating testability from efficacy.